Sensus Healthcare, Inc. (SRTS) - Q2 2025 10-Q Summary
Business Context and Reporting Period
Sensus Healthcare, Inc. is a medical device company manufacturing radiation therapy devices (SRT-100, SRT-100+, SRT-100 Vision) for oncological and non-oncological skin conditions. The company operates globally with a primary focus on the U.S. dermatology market. This report covers the quarterly period ended June 30, 2025.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Revenue | $7.3 million | $9.2 million | $15.7 million | $19.9 million |
| Gross Profit | $2.9 million | $5.4 million | $7.3 million | $12.1 million |
| Gross Margin | 39.7% | 58.7% | 46.5% | 60.8% |
| Operating Loss | ($1.9 million) | $2.0 million (Income) | ($4.6 million) | $4.9 million (Income) |
| Net Loss | ($1.0 million) | $1.6 million (Income) | ($3.6 million) | $3.9 million (Income) |
| Cash and Equivalents | $22.2 million (as of June 30, 2025) | |||
| Operating Cash Flow (YTD) | $0.4 million | ($4.0 million) | ||
| Debt | $0 outstanding (Revolving credit facility: $15M available) |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 20.7% QoQ and 21.1% YTD compared to the prior year. This was primarily driven by a lower number of units sold to a single large U.S. customer, who accounted for 56% of Q2 2025 revenue (down from 83% in Q2 2024).
- Margin Compression: Gross margin dropped significantly from 58.7% to 39.7% in Q2 2025. Management attributed this to lower sales volume, higher costs of servicing systems, and costs associated with a new placement program.
- Expense Increases: Operating expenses rose sharply. R&D expenses increased 66.7% QoQ due to next-generation system development. Selling and marketing expenses rose 40.0% due to tradeshows and clinical studies. G&A increased 25.0% due to professional fees and compensation.
- Profitability Shift: The company swung from a net income of $1.6 million in Q2 2024 to a net loss of $1.0 million in Q2 2025.
Outlook, Risks, and Contingencies
- Liquidity: The company holds $22.2 million in cash and has a $15 million revolving credit facility with Comerica Bank (no borrowings outstanding). Management believes current resources are sufficient for the next 12 months.
- Customer Concentration Risk: A single U.S. customer represents a significant portion of revenue (56% in Q2 2025) and accounts receivable (78% as of June 30, 2025).
- Legal Contingency: The Department of Justice is investigating billing practices by a physician using Sensus devices. The investigation may expand to the Company. While the Company disputes wrongdoing and has not estimated a cost, it remains a material contingency.
- Geopolitical and Economic Risks: The filing notes monitoring of geopolitical conflicts (Middle East, Ukraine) and inflationary pressures on commodity, shipping, and labor costs.
- Stock Repurchases: The company repurchased 50,360 shares for $300,000 during the six months ended June 30, 2025.
Investor Verification Checklist
- Customer Dependency: Verify the stability of the relationship with the primary U.S. customer, as they represent over half of quarterly revenue.
- Margin Recovery: Assess the sustainability of the new placement program costs and whether gross margins can return to historical levels (~60%) as sales volume stabilizes.
- DOJ Investigation: Monitor updates regarding the Department of Justice investigation into physician billing codes to gauge potential liability or reputational impact.
- R&D Pipeline: Evaluate the timeline and commercial viability of the "next generation systems" driving the 66% increase in R&D spend.
- Cash Burn vs. Revenue: Confirm that the shift to positive operating cash flow ($0.4M YTD 2025 vs. negative $4.0M YTD 2024) is sustainable despite the net loss.